• Semaglutide 1.7mg: GLP-1 receptor agonist — mimics the natural incretin hormone to reduce appetite and blood sugar
• Weekly subcutaneous injection
• FDA-approved for chronic weight management (obesity/overweight)
• Prescription-only

• Semaglutide 1.7mg — advanced titration dose for progressive weight loss
• GLP-1 mechanism reduces appetite, increases satiety, slows gastric emptying
• Part of the structured Wegovy dose escalation programme
• Clinically proven — patients lose on average 15% of body weight
• Cardiovascular and metabolic benefits beyond weight loss

• Weekly injection on the same day each week
• Used as part of the Wegovy titration schedule after tolerating 1.0mg
• As prescribed by your endocrinologist or obesity specialist
• Combined with diet and exercise programme
• Subcutaneous injection into abdomen, thigh, or upper arm

• PRESCRIPTION MEDICATION — use only under medical supervision
• Not for use in Type 1 diabetes
• Contraindicated with personal or family history of medullary thyroid carcinoma (MTC)
• Monitor for signs of pancreatitis (severe abdominal pain)
• Common side effects: nausea, vomiting, diarrhoea, constipation
• Tell your doctor about all medications
• Keep refrigerated; do not freeze

• Self-inject subcutaneously once weekly
• Rotate injection sites each week
• Can be injected with or without food
• Store in refrigerator (2°C–8°C)
• Dispose of used pen safely in a sharps container
• Follow your doctor's instructions on injection technique

What is the titration schedule for Wegovy? Doses escalate: 0.25mg → 0.5mg → 1.0mg → 1.7mg → 2.4mg (maintenance), each held for 4 weeks.

Will I regain weight if I stop? Weight may return after stopping — Wegovy is a long-term treatment.

Does it treat diabetes? Wegovy is for weight management; Ozempic (same drug) is for Type 2 diabetes.